A new era in HIV vaccine development

被引：2

作者：

Lau, Chuen-Yen ^{[1
]}

Velasco, Peter P. ^{[1
]}

Johnston, Margaret I. ^{[1
]}

机构：

[1] NIH, NIAID, Div Aids, Vaccine Res Program, Bethesda, MD 20817 USA

来源：

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2007年 / 5卷 / 02期

关键词：

AIDS vaccine; collaboration; HIV vaccine; product development;

D O I：

10.1586/14787210.5.2.205

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Since the identification of HIV in 1984, the search for a safe and effective vaccine has been relentless. While investigator-initiated research has provided substantial information regarding HIV disease and pathogenesis, and over two dozen drugs are licensed in the USA to treat HIV, the global epidemic continues unabated. Early in HIV vaccine research, the pharmaceutical industry took the initiative to produce products for clinical testing. As the likelihood of a quick success decreased, private investment waned. The public sector responded with novel mechanisms to engage industry while continuing to support academic investigators. HIV vaccine research continues to rely on the creativity of individual investigators, as well as collaborations that vary in size and complexity and offer opportunities for the efficient use of resources and accelerated progress.

引用

页码：205 / 215

页数：11

共 62 条

[61] Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E [J].

Wang, Shixia ;

Pal, Ranajit ;

Mascola, John R. ;

Chou, Te-Hui W. ;

Mboudjeka, Innocent ;

Shen, Siyuan ;

Liu, Qin ;

Whitney, Stephen ;

Keen, Timothy ;

Nair, B. C. ;

Kalyanaraman, V. S. ;

Markham, Philip ;

Lu, Shan .

VIROLOGY, 2006, 350 (01) :34-47

[62] Research funding - NIH in the post-doubling era: Realities and strategies [J].

Zerhouni, Elias A. .

SCIENCE, 2006, 314 (5802) :1088-1090

← 1 2 3 4 5 6 7 →